IPM Biotech - Immunogenicity

Biological drugs have revolutionized the therapy of numerous diseases. Millions of patients have benefited from specific treatments using biopharmaceuticals.

Unwanted adverse immune reactions against biopharmaceuticals may lead to reduced efficacy of the drugs and even to severe clinical complications. Therefore, it is of great interest to establish methods to identify, characterize and monitor immune reactions.

IPM BIOTECH attempts to resolve immunogenicity by antibody detection against biopharmaceuticals using a broad range of methods and different assay formats:

Binding antibodies

- - Radio-immuno-precipitation assay(RIPA)

- - Electrochemiluminescence (ECL) (MSD)

- - ELISA (incl. bridging, ACE)

- - FEIA (for spec. IgE testing)

- - Luminescence assays

- - SPR (BiaCore)

Neutralizing antibodies

- - Proliferation assays

- - Gene expression assays

- - Gene reporter assays

- - Activity assays

Please contact for any needs in immunogenicity:

PD Dr. Arno Kromminga

Tel.	+49 (0) 4053805 165
Mobile:	+49 (0) 179 456 8491
Email:	arno.kromminga@ipm-biotech.de